The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine, are frequently prescribed for several types of cancer, including breast, colorectal, head and neck and gastric cancer. In the current drug labels of 5-FU and capecitabine in the European Union and the United States, no adaptive dosing strategies are incorporated for polymorphic metabolism of 5-FU. Although treatment with fluoropyrimidines is generally well tolerated, a major clinical limitation is that a proportion of the treated population experiences severe, sometimes life-threatening, fluoropyrimidine-related toxicity. This toxicity is strongly affected by interindividual variability in activity of dihydropyrimidine dehydrogenase (DPD), the main metabolic enzyme for inactivation of fluoropyrimidines, with an estimated 3%-8% of the population being partially DPD deficient. A reduced functional or abrogated DPD enzyme is often caused by genetic polymorphisms in DPYD, the gene encoding for DPD, and heterozygous carriers of such DPYD polymorphisms have a partial DPD deficiency. When these partially DPD deficient patients are treated with a full dose of fluoropyrimidines, they are generally exposed to toxic levels of 5-FU and its metabolites, and the risk of developing severe treatment-related toxicity is therefore significantly increased. Currently, functional and clinical validity is well established for four DPYD variants (DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A), as those variants have retrospectively and in a large population study prospectively been shown to be associated with increased risk of fluoropyrimidine-associated toxicity. Patient safety of fluoropyrimidine treatment can be significantly improved by pre-emptive screening for DPYD genotype variants and dose reductions in heterozygous DPYD variant allele carriers, thereby normalizing 5-FU exposure. Based on the critical appraisal of currently available data, adjusting the labels of capecitabine and 5-FU by including recommendations on pre-emptive screening for DPYD variants and DPYD genotype-guided dose adjustments should be the new standard of care.
Introduction
Fluoropyrimidines, a group of anticancer drugs including 5-fluorouracil (5-FU) and its oral prodrugs capecitabine (Xeloda V R ) and tegafur (active compound of S-1, Teysuno V R ) have been the backbone of anticancer treatment in a variety of cancers, including breast, colorectal, head and neck, anal, pancreas and gastric cancer, for over 50 years. These drugs are among the most frequently prescribed anticancer drugs, as an estimated two million patients are treated with fluoropyrimidines each year [1, 2] . Despite convincing evidence, no dose individualization strategies are recommended for polymorphic metabolism of 5-FU in the current drug labels of the fluoropyrimidines drugs 5-FU and capecitabine.
Although the majority of patients can be treated safely with capecitabine and 5-FU, a substantial proportion experiences severe fluoropyrimidine-related toxicity [3, 4] . For example, in phase III studies in metastatic colorectal cancer, 30%-40% of the patients treated with 5-FU or capecitabine monotherapy experienced severe (grade 3) treatment-related toxicity, mainly consisting of diarrhea, mucositis, bone marrow suppression, and hand-foot syndrome [5, 6] . Treatment of severe toxicity is usually associated with interruption or even discontinuation of potentially effective anticancer therapy, and often requires hospitalization, which also increases healthcare costs. Furthermore, severe fluoropyrimidine-related toxicity leads to mortality in 0.5%-1% of patients [5] [6] [7] [8] . This indicates that fluoropyrimidineassociated toxicity is a substantial clinical problem.
In this review, the current knowledge on metabolism of fluoropyrimidines, available methods to test for dihydropyrimidine dehydrogenase (DPD) activity and associations between DPD deficiency and fluoropyrimidine-related toxicity are described. The benefits of fluoropyrimidine dose individualization based on genotyping for DPYD polymorphisms that reduce DPD activity are outlined, supporting our call for an update of the drug label of the fluoropyrimidine drugs capecitabine and 5-FU and to include dose individualization strategies based on DPYD genotype.
Metabolism of fluoropyrimidines
After administration, the prodrug capecitabine is stepwise converted into 5-FU. Only a small fraction of 5-FU (1%-5%) is converted intracellularly into the cytotoxic metabolites fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine triphosphate (FUTP; Figure 1 ) [9, 10] . Besides this, the DPD enzyme converts 80% of the administered dose of 5-FU into the inactive metabolite 5,6-dihydro-5-fluorouracil (FUH 2 ), which makes DPD the rate-controlling enzyme for inactivation of 5-FU (Figure 1 ) [9] [10] [11] . The amount of 5-FU available for conversion into cytotoxic metabolites is therefore primarily determined by systemic DPD activity. The DPD enzyme is mainly expressed in the liver, the main site of 5-FU metabolism. DPD activity varies widely between patients, with an estimated 3%-8% of the population being partially DPD deficient, having an approximately up to 50% lower enzymatic activity [12, 13] . Complete DPD deficiency (0% enzyme activity) is much rarer than partial deficiency, with an estimated incidence of 0.1% [12, [14] [15] [16] . When partially DPD deficient patients are treated with standard doses of fluoropyrimidines, the reduced DPD activity will result in decreased inactivation of 5-FU, thereby increasing levels of active metabolites of 5-FU, which is associated with a strongly increased risk of severe and even fatal toxicity [13, 17, 18] . Several studies showed that around 39%-61% of patients with severe fluoropyrimidine-associated toxicity were found to have decreased DPD activity [19] [20] [21] .
DPD deficiency is most often the result of genetic polymorphisms in DPYD, the gene encoding the DPD enzyme. DPYD is a highly polymorphic gene with over 35 genetic polymorphisms in DPYD described, among which several lead to reduced function or a non-functional DPD enzyme, such as DPYD*2A, c.2846A>T, c.1679T>G, and c.1236G>A [18, 22, 23] . It is estimated that around half of the DPD deficient cases can be identified by these four DPYD variants [24] .
Carriers of functionally relevant DPYD variants are likely to be subject to increased 5-FU exposure when treated with standard dose of fluoropyrimidines. By upfront screening for DPYD variants followed by adjusting the fluoropyrimidine starting dose in partially DPD deficient patients, high 5-FU exposure in these patients can be avoided and therapeutic exposure achieved, thereby reducing risk of severe treatment-related toxicity [25] [26] [27] .
Methods for testing for DPD deficiency
Several strategies for testing for DPD deficiency have been developed, which are based on either genotyping of DPYD or measurement of the DPD phenotype. A genotype-based approach consists of testing for single nucleotide polymorphisms in DPYD and advantages include high diagnostic accuracy, since results are unambiguous and the test is not influenced by environmental factors. Furthermore, this test is relatively easy to implement in diagnostic laboratories of hospitals [24] . Evidence-based dose recommendations are available on how to dose fluoropyrimidines in the case a patient carries a DPYD polymorphism [28, 29] and this will be described in more detail in the paragraph on dose individualization.
Other strategies for determination of DPD deficiency are methods measuring the DPD phenotype. These methods include measuring DPD enzyme activity in peripheral blood mononuclear cells (PBMCs), or measurement of in vivo concentrations of the endogenous substrate of DPD, uracil, and its metabolic product dihydrouracil, either after a loading dose of uracil or the endogenous plasma levels of dihydrouracil and uracil [24, 30] . Compared with a genotype-based approach, these methods are considered more difficult to implement as a routine diagnostic test, as these methods are often more time-consuming and materials and equipment might not be available in every hospital. In addition, limited information is available on how to adjust the dose in patients with DPD deficiency identified by DPD phenotyping tests, and additional studies on clinical validity and utility are required before clinical implementation [24, 30] . A promising aspect of DPD phenotyping tests is that sensitivity to identify DPD deficiency might be increased when used in addition to DPYD genotyping tests, as currently not all DPD deficiency can be attributed to a genetic alteration in DPYD.
Examples of current information on DPD deficiency in fluoropyrimidine drug labels
In the European Union, DPD deficiency is mentioned in the current version of the summary of product characteristics (SPC) of capecitabine in the sections Contraindications and Special warnings and precautions for use [31] . It is stated that capecitabine is contraindicated in patients with known complete absence of DPD activity. As a special warning it is mentioned that severe, life-threatening, or fatal adverse reactions have been attributed to DPD deficiency. However, no obligations or recommendations on pre-emptive testing for DPD deficiency are mentioned in the SPC and it is also stated that there is insufficient data to recommend specific dose reductions in patients with partial DPD activity. Similar information on DPD deficiency is provided in the United States by the Food and Drug Administration (FDA) in the package insert of capecitabine [32] . The same accounts for the SPC and FDA label of 5-FU [33, 34] .
Despite strong evidence linking DPYD variants to severe toxicity, pharmacogenetic testing for DPYD polymorphisms is currently not described in the drug label. We recently informed health authorities (European Medicines Agency (EMA), Dutch Medicines Evaluation Board (MEB), and FDA) and encouraged companies holding marketing authorization applications to request adjusting the drug labels of capecitabine and 5-FU. Recently published studies [26, 35] add to the numerous available studies published over many years, supporting pre-emptive DPYD genotyping and dose individualization. Patient safety of fluoropyrimidine therapy can be substantially improved, if dose adjustments based on DPYD genotype are finally implemented worldwide.
Dose individualization based on DPYD genotype
DPYD*2A genotype DPYD*2A (IVS14þ1G>A; c.1905þ1G>A; rs3918290) is the most widely studied polymorphism in DPYD and was the first variant described as being functionally relevant [36] . Allele frequencies of DPYD*2A have been reported to vary between 0.1% and 1.0% in African-American and Caucasian populations, respectively [23, 28, 37, 38] . DPYD*2A leads to skipping of the entire exon 14 and deletion of 165 base pairs, which results in a truncated protein that is catalytically inactive [36, 39] . This is supported by an in vitro study by Offer et al. in which several DPYD variants were homozygously expressed in mammalian cells and the enzymatic activity of expressed protein was completely absent when expressing DPYD*2A [40] and patients with complete DPD deficiency that were identified as homozygous DPYD*2A variant allele carriers [36, 38, 41] . This suggests that in heterozygous carriers of this variant, who have one dysfunctional allele and one functional allele, 50% of the normal DPD enzyme activity will be retained. The DPYD*2A variant has been associated with 50% decreased DPD enzyme activity in PBMCs in several ex vivo studies [19, 39, 42, 43] . This DPD activity in PBMCs is well correlated with DPD activity in the liver, the main site of 5-FU metabolism [44] . In addition, in heterozygous DPYD*2A carriers 5-FU clearance was found to be significantly reduced, resulting in increased exposure to 5-FU and active metabolites [45] [46] [47] .
Clinical validity and utility of DPYD*2A genotypeguided dosing Data on DPYD*2A and toxicity from retrospective studies are numerous. In many studies and two recent meta-analyses increased risk of toxicity related to fluoropyrimidine treatment in DPYD*2A variant allele carriers was confirmed [18, 35, 37, 45, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] .
The clinical utility of DPYD*2A-guided dosing to prevent severe toxicity was recently investigated in the prospective clinical trial by Deenen et al. [26, 27] . Patients intended to be treated with fluoropyrimidine-based chemotherapy were genotyped for DPYD*2A before start of therapy. In view of the predictable effect on DPD activity and 5-FU pharmacokinetics, DPYD*2A variant allele carriers received an initial dose reduction of 50%. This initial dose reduction could be followed by dose-titration based on tolerance. Of the 1631 patients screened and treated with fluoropyrimidines, 18 patients (1.1%) were found to be a heterozygous DPYD*2A carrier [26] . Toxicity data for variant allele carriers treated with a reduced dose were compared with historical controls from literature, i.e. DPYD*2A variant allele carriers receiving standard dose. Given the strong association between DPYD*2A and increased risk of severe and lethal toxicity, a randomized clinical trial, in which DPYD*2A carriers would receive a full fluoropyrimidine dose, was considered unethical. The study showed that risk of severe (grade 3) treatment-related toxicity was significantly lower in DPYD*2A variant allele carriers undergoing genotype-guided dosing than in the historical controls, respectively, 28% and 73% (P < 0.001). Drug-related death was reduced from 10% in historical controls to 0% in this study. The DPYD*2A genotype-guided dosing strategy resulted in comparable severe toxicity risk when compared with patients wild-type for DPYD*2A given standard-dose therapy (23%, P ¼ 0.64) [26] .
c.2846A>T, c.1679T>G, and c.1236G>A genotype Because the frequency of DPYD*2A in Caucasian patients is around 1%, it provides only limited sensitivity to identify patients at risk of severe toxicity. Additional DPYD variants have been identified that are associated with DPD deficiency. Clinical validity has currently been established for three other DPYD variants (c.2846A>T, c.1679T>G, and c.1236G>A).
The c.2846A>T variant allele (D949V; rs67376798) was first described by van Kuilenburg et al. [19] . The c.2846A>T polymorphism leads to a structural change in the DPD enzyme that interferes with cofactor binding or electron transport [61] . Reported allele frequencies of c.2846A>T vary from 0.1% to 1.1% in African-Americans and Caucasians, respectively [23, 28, 37, 62] . In vitro data from Offer et al. show that homozygous expression of the c.2846A>T variant results in an activity of 59% compared with wild-type (P ¼ 0.0031) [23] . Although the enzyme activity of c.2846A>T is significantly impaired, it is not comparable to the extent observed for DPYD*2A, where homozygous expression resulted in a completely non-functional enzyme [40] . This finding that homozygous expression of c.2846A>T results in 50% reduction, implies that a heterozygous carrier would have around 25% reduction in DPD activity, and would benefit from a 25% dose reduction [29] .
The DPYD variant c.1679T>G (DPYD*13; I560S; rs55886062) is a very rare DPYD variant, with an allele frequency found to vary from 0.07% to 0.1% in Caucasians [28, 37] . Homozygous expression of this variant resulted in a 75% reduction of DPD enzyme activity compared with wild-type, as reported in an in vitro study by Offer et al. [40] . This suggests that this variant almost completely inactivates the protein, and that heterozygous carriers would have around 50% reduction in DPD enzyme activity [29] . Decreased DPD enzyme activity in patients carrying the c.1679T>G variant was determined in a limited number of ex vivo studies using PBMCs [42, 43, 61, 63] .
The c.1236G>A polymorphism (E412E; rs556038477) occurs in exon 11 and is a synonymous variant that is in complete linkage with c.483þ18G>A, c.680þ139G>A, c.959-51T>G, and c.1129-5923C>G; these variants in linkage have been termed haplotype B3 (HapB3) [64, 65] . The c.1129-5923C>G intronic polymorphism (rs75017182) results in aberrant splicing and is likely to be responsible for the effect on DPD enzyme activity [17, 65] . The frequency of heterozygous patients in Caucasian populations was reported to vary between 2.6% and 6.3% [57, [64] [65] [66] [67] . DPD enzyme activity in PBMCs in c.1236G>A/HapB3 carriers was found to be reduced [65] . As DPD activity is not completely absent in homozygous carriers of this DPYD polymorphism, it is expected that a 25% dose reduction for heterozygous carriers is suitable [29, 68] .
Clinical validity of c.2846A>T, c.1679T>G, and c.1236G>A genotype-guided dosing Meulendijks et al. have investigated associations between DPYD variants and severe fluoropyrimidine-associated toxicity to determine clinical validity in a recent systematic review and metaanalysis using individual patient data [35, 69] . A total of 7356 patients from 8 studies were included in the analysis. DPYD c.1679T>G was found to be significantly associated with fluoropyrimidine-induced severe toxicity (relative risk 4.40, 95% CI 2.08-9.30, P < 0.0001). Also c.1236G>A was significantly associated with fluoropyrimidine-induced severe toxicity (relative risk 1.59, 95% CI 1.29-1.97, P < 0.0001). For c.2846A>T a significant association with severe toxicity was found as well (relative risk 3.02, 95% CI 2.22-4.10, P < 0.0001) [35] . These results show that c.1679T>G, c.1236G>A, and c.2846A>T are clinically relevant predictors of fluoropyrimidine-associated toxicity, in addition to the DPYD*2A variant.
Judging from the data on functional and clinical relevance of these variants, it can be expected, in line with recommended dose adjustments for heterozygous DPYD*2A carriers, that initial dose reductions in heterozygous carriers of these three other DPYD polymorphisms (as described in Table 1 ) will result in normalization of 5-FU exposure and reduction in the risk of severe toxicity as well.
For the DPYD variants c.2846A>T and c.1679T>G, in addition to DPYD*2A, initial dose reductions are recommended in the guidelines of the Clinical Pharmacogenetics Implementation Consortium (CPIC) [28] . c.1236G>A/HapB3 is not yet included in this guideline (published in 2013).
The dose recommendations for these four DPYD variants are considered initial recommendations. If treatment is considered safe after two cycles of chemotherapy, based on clinical and laboratory assessments, individual dose up titration can be applied, to achieve maximum safe exposure in all patients.
Cost-effectiveness of DPYD genotype-guided dosing
The occurrence of severe fluoropyrimidine-related toxicity does not only have an impact on the patient itself, but can also result in significant health care costs, with high costs for medication to treat side-effects and hospitalization. If DPYD genotyping (costs around e75 to e100 per patient) and individualized dosing can decrease the incidence of severe toxicity, it can be expected that costs of health care will decrease as well. This was investigated in two studies [26, 70] .
The prospective study by Deenen et al. included a model-based cost-analysis, from a health care payer perspective (including only direct medical costs) [26] . The average total treatment costs per patient were shown to be slightly lower (e2772) for upfront DPYD*2A-screening than for non-screening (e2817) [26] .
In a study by Mercier et al. a comparison was made between 74 patients with head and neck cancer receiving standard dosage of 5-FU and 74 patients that received a dose reduction if considered DPD-deficient (tested phenotypically) [70] . Direct and indirect costs for managing treatment-related toxicities were taken into account. It was shown that there was a large reduction in treatment costs for toxicity per patient if applying individualized dosing guided by DPD-status, from $6279 in the group with standard dosing versus $294 in the group with adaptive dosing based on DPD-status [70] . Based on these studies, dose individualization based on DPYD genotype or DPD phenotype is shown to be cost-saving.
Benefit-risk assessment and uncertainties in DPYD genotype-guided dosing ) area under the plasma concentration-time curve (AUC) of 5-FU proved to be twice as high in patients with the DPYD*2A genotype compared with the exposure in the wild-type control population [26] . These results show that adequate systemic exposure to 5-FU is achieved following a 50% dose reduction, and therefore it is unlikely that efficacy is negatively influenced by dose reductions in patients with partial DPD deficiency. Furthermore, several studies have been carried out that investigated the effect on efficacy of dose individualization based on DPD phenotyping tests. Although these studies all had a small sample size and results should therefore be interpreted with caution, in all studies, reducing the dose in patients with partial DPD deficiency did not negatively affect treatment efficacy [70] [71] [72] . These studies used different methods than the DPYD genotyping proposed here, but as there is a clear correlation between DPYD genotype and DPD phenotype, these clinical reports support the expectation that efficacy is unlikely to be negatively influenced by dose reductions in patients with partial DPD deficiency.
Risks of DPYD genotype-guided dosing of fluoropyrimidines
Risk of severe fluoropyrimidine-related toxicity can be significantly reduced when applying an initial dose reduction in DPYD variant allele carriers. However, not all toxicity can be prevented with this strategy, as there are other factors influencing DPD enzyme activity as well, and not all treatment-related toxicity can be explained by DPD deficiency. Nevertheless, if with upfront DPYD genotypeguided dose individualization risk of severe fluoropyrimidinerelated toxicity in DPYD variant allele carriers can be reduced until background risk of toxicity (risk for DPYD wild-type patients), patient safety will be significantly improved.
Uncertainties of DPYD genotype-guided dosing and benefit-risk balance Dose recommendations for DPYD variant allele carriers (Table 1) are based on in vitro and in vivo data, and are expected to be suitable for the majority of patients. However, as DPD activity is known to have a high interindividual variability, these dose recommendations may not be the ideal recommendation for all patients. This limitation can partly be prevented if individual dose titration (upward or downward) based on tolerance is applied after the first two cycles of treatment. Most studies focus on heterozygous carriers of DPYD variants. Much rarer are patients who are homozygous carriers of a specific DPYD variant or carriers of multiple DPYD variants simultaneously on different alleles (the so-called compound heterozygous), and therefore recommendations for a suitable dose for such patients are more difficult. Patients with a homozygous DPYD variant genotype for variants such as DPYD*2A are expected to have no residual DPD activity, and therefore treatment with a fluoropyrimidine is discouraged. For a homozygous DPYD genotype of a variant with a more modest effect on DPD activity (such as c.1236G>A) or a compound heterozygous DPYD genotype, the effect on the DPD phenotype is more difficult to predict. When a patient with such a rare genotype is identified, we advise to perform additional tests, such as determining enzyme activity in PBMCs, before deciding on an individual treatment plan.
The DPYD variants described in this review are especially relevant for Caucasians, as most studies focused on patients of this ethnic origin. For ethnicities other than Caucasians, more research on the frequency and clinical relevance of these and other DPYD variants is recommended.
Currently, most evidence on clinical validity and utility is available for individualized dosing based on DPYD genotype. However, several DPD phenotyping tests are being developed that have the potential to increase sensitivity to identify DPD deficient patients. Before these tests could be implemented as standard of care, further studies are required.
As described, the number of prospective studies investigating clinical utility of DPYD genotype-guided dosing is still limited. However, based on the wealth of evidence from retrospective studies, it can be concluded that there is a clear correlation between DPYD genotype, 5-FU metabolism and fluoropyrimidineassociated toxicity, which makes DPYD genotype-guided dose individualization the logical next step.
Weighing the available data on efficacy of DPYD genotypeguided dosing against the substantial decrease in risk of severe fluoropyrimidine-related toxicity that can be achieved, it is concluded to recommend DPYD genotype-guided screening and dose individualization of fluoropyrimidines.
Discussion
Conclusions and recommendations on a fluoropyrimidine label update
As fluoropyrimidine drugs such as capecitabine and 5-FU are the cornerstone in anticancer treatment of a variety of cancers, fluoropyrimidine-related toxicity remains a major clinical problem. It is known that carriers of the DPYD variants are at significantly increased risk of developing severe fluoropyrimidine-related toxicity. Strong evidence is currently available for an association with increased risk of severe toxicity for four DPYD variants (DPYD*2A, c.1679T>G, c.2846A>T, and c.1236G>A/HapB3). Dose recommendations for these variants are available. When applying an initial dose reduction of fluoropyrimidine therapy, this risk of severe toxicity can be strongly reduced.
Despite a wealth of evidence, upfront testing for DPD deficiency in patients treated with fluoropyrimidines and dose individualization based on DPYD genotype is still not officially recommended and not included in the drug label. Also guidelines, including the ESMO consensus guideline for the management of patients with metastatic colorectal cancer, are reluctant in recommending upfront screening for DPD deficiency [73] . However, risk on severe fluoropyrimidine-related toxicity substantially decreases, without risk of underdosing, when upfront DPYD genotype screening followed by dose adjustments in variant allele carriers will become part of routine clinical practice. In this way, important anti-cancer drugs such as 5-FU and capecitabine do not have to be withheld from partially DPD deficient patients.
Based on the review of available data, adjusting the drug labels of capecitabine and 5-FU products is recommended. It is time to change standard of care and screening for DPD deficiency should be carried out before start of treatment and included in the label of fluoropyrimidine drugs. After reviewing our proposal, the EMA has now asked the involved pharmaceutical companies to update the SPC of fluoropyrimidines by including information on DPYD-genotyping and genotype-guided dosing.
Based on the currently available literature there is convincing evidence for genotype-guided screening for four DPYD variants (DPYD*2A, c.2846A>T, c.1679T>G, and c.1236G>A). DPYDgenotyping is a pre-emptive test that can be easily carried out in clinical laboratories. In case of heterozygous carriers of these DPYD polymorphisms (partial DPD deficiency) an initial dose reduction should be recommended, consisting of dose recommendations for these four polymorphisms, as shown in Table 1 . These dose recommendations apply both to fluoropyrimidine monotherapy as well as combination therapy with other chemotherapeutic agents or radiotherapy. After initially reducing the fluoropyrimidine starting dose, further individual dose titration (upward or downward) based on tolerance is recommended, to guarantee maximum safe drug exposure in all patients. For patients with a complete DPD deficiency (no residual DPD activity, for example homozygous DPYD*2A variant allele carriers) fluoropyrimidine treatment should remain contra-indicated and selection of alternative treatment is recommended.
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